These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18308462)

  • 1. Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer.
    Koltz L; Clarke N
    Eur Urol; 2008 May; 53(5):1079-83. PubMed ID: 18308462
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer: a serious disease suitable for prevention.
    Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
    BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is premature.
    Frankel PH; Twardowski P
    J Clin Oncol; 2009 Oct; 27(30):e164; author reply e165. PubMed ID: 19738114
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of 5α-reductase inhibitors for the prevention and treatment of prostate cancer.
    Cha EK; Shariat SF
    Eur Urol; 2011 Apr; 59(4):515-7. PubMed ID: 21277077
    [No Abstract]   [Full Text] [Related]  

  • 6. Implementation of the Prostate Cancer Prevention Trial (PCPT).
    Goodman PJ; Tangen CM; Crowley JJ; Carlin SM; Ryan A; Coltman CA; Ford LG; Thompson IM
    Control Clin Trials; 2004 Apr; 25(2):203-22. PubMed ID: 15020037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proscar and propecia--a therapeutic perspective.
    Palusinski R; Barud W
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6359. PubMed ID: 15579805
    [No Abstract]   [Full Text] [Related]  

  • 8. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible.
    Roehrborn CG; Lotan Y; Tubaro A; de Nunzio C
    Eur Urol; 2006 Feb; 49(2):396-400. PubMed ID: 16455190
    [No Abstract]   [Full Text] [Related]  

  • 9. Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea.
    Beer TM
    Health News; 2003 Aug; 9(8):1-2. PubMed ID: 12971313
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of prostate cancer with finasteride.
    Burke HB
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562806
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)].
    Aliaev IuG; Vinarov AZ; Lokshin KL; Spivak LG
    Urologiia; 2006; (6):83-6. PubMed ID: 17315721
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
    Finelli A; Trottier G; Lawrentschuk N; Sowerby R; Zlotta AR; Radomski L; Timilshina N; Evans A; van der Kwast TH; Toi A; Jewett MA; Trachtenberg J; Fleshner NE
    Eur Urol; 2011 Apr; 59(4):509-14. PubMed ID: 21211899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finasteride for prevention of prostate cancer.
    Med Lett Drugs Ther; 2008 Jun; 50(1289):49-50. PubMed ID: 18583946
    [No Abstract]   [Full Text] [Related]  

  • 16. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
    Marks LS; Andriole GL; Fitzpatrick JM; Schulman CC; Roehrborn CG
    J Urol; 2006 Sep; 176(3):868-74. PubMed ID: 16890642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of prostate cancer with finasteride.
    Barzell WE
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562803
    [No Abstract]   [Full Text] [Related]  

  • 18. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed reviews for drug studied to prevent prostate cancer.
    Mayo Clin Health Lett; 2003 Oct; 21(10):4. PubMed ID: 14619781
    [No Abstract]   [Full Text] [Related]  

  • 20. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.